abstract |
The present invention relates to TRAF2 variants exhibiting the ability to inhibit the TNF a signaling pathway. In particular, a splice variant of TRAF2, referred to herein as "TRAF2 cleavage" or "TRAF2TR", separates a TRAF2 expression construct that has been enhanced in its major negative capacity, called "TRAF2 cleaved deletion" or "TRAF2TD". Both TRAF2TR and TRAF2TD have the ability to inhibit the TNF α signaling pathway, and in the case of TRAF2TD this ability is greatly enhanced, significantly reducing the response to TNF α binding. |